Biotie today reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant. Dr. C Warren Olanow, Professor of Neurology and Neuroscience at the Mount Sinai School of Medicine stated "This important study demonstrated that the A2a antagonist tozadenant reduced 'off' time in advanced PD patients. This agent, which does not act directly on the dopamine system, represents a new class of therapeutic agent that could be used to aid in the management of patients with this potentially disabling disorder."
seemingly adenosine is also blocked by coffee.